Why Citizens JMP Backed Viant in November After EBITDA Beat and ex‑TAC Strength
On November 11, one day after Viant’s Q3 print (Nov 10), Citizens JMP’s Matthew Condon maintained “Market Outperform” and trimmed the price target to $16 from $18, citing a strong quarter.






